The economic burden of elevated blood glucose levels in 2017 in the United States
Life Sciences Research & Analysis The economic burden of elevated blood glucose levels in 2017 in the United States 26 September 2019 Timothy...
A trained health economist, he brings more than 20 years of experience conducting research and policy analysis in the areas of health economics and outcomes, health workforce, health care delivery and disease cost and prevention. His work applies economic theory, statistical and econometric analysis, cost/benefit analysis, program evaluation, and computer modeling skills. Much of his work uses microsimulation modeling to address complex forecasting and policy issues. Applied research conducted by Mr. Dall supports strategic planning and advocacy work for governments, associations, life sciences companies, payers, provider networks, and non-profit organizations. He has published widely in peer-reviewed journals. Mr. Dall earned his Master of Science in Labor Economics at the University of Wisconsin-Madison, US, and his Bachelor of Science in Economics from Utah State University, Logan, Utah, US.
Following the executive order on 13 September to lower drug prices in the United States, the battleground over US healthcare is taking shape and could fundamentally impact the outlook of the global pharmaceutical industry—all while the coronavirus disease 2019 (COVID-19) pandemic continues to dominate the political agenda.